Extension of microglial activation is associated with epilepsy and cognitive dysfunction in Tuberous sclerosis complex: A TSPO-PET study

• Published in: NeuroImage clinical Vol. 37; p. 103288
• Main Authors: Kagitani-Shimono, Kuriko, Kato, Hiroki, Soeda, Fumihiko, Iwatani, Yoshiko, Mukai, Masashi, Ogawa, Katsuhiro, Tominaga, Koji, Nabatame, Shin, Taniike, Masako
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Inc 01-01-2023; Elsevier
• Subjects: Cognitive Dysfunction - complications; Cognitive Dysfunction - etiology; Cross-Sectional Studies; Epilepsy; Epilepsy - complications; Epilepsy - etiology; Humans; Microglia; Neuroinflammation; Neuroinflammatory Diseases; Positron-Emission Tomography - methods; Receptors, GABA - metabolism; Regular; Seizures - complications; TAND; Tomography, X-Ray Computed; TOR Serine-Threonine Kinases - metabolism; TSPO-PET; Tuberous Sclerosis - complications; Tuberous Sclerosis - diagnostic imaging; Tuberous Sclerosis - metabolism; Tuberous sclerosis complex; TAND; Epilepsy; TSPO-PET; SEGA; DQ; GASE; ASD; WI; VABS; mTOR; TSPO; SUVr; FLAIR; ID; AML; AED; IL; TSC; DEE; EEG; IQ; Neuroinflammation; LST; ICV; SEN; Tuberous sclerosis complex; PET; KSPD
• ISSN: 2213-1582; 2213-1582
• DOI: 10.1016/j.nicl.2022.103288

•TSC causes overactivation of the mTOR pathway, which is linked to neuroinflammation.•Most cortical tubers in TSC patients showed microglial activation.•Microglial activation was far greater in refractory seizure patients.•Microglial activation was reduced in patients treated with mTOR-inhibitor.•Microglial activation is correlated with epilepsy severity and cognitive dysfunction.
Neuroinflammation contributes to the severity of various neurological disorders, including epilepsy. Tuberous sclerosis complex (TSC) is a condition that results in the overactivation of the mammalian target of rapamycin (mTOR) pathway, which has been linked to the activation of microglia responsible for neuroinflammation. To clarify the involvement of neuroinflammation in the neuropathophysiology of TSC, we performed a positron emission tomography (PET) study using the translocator protein (TSPO) radioligand, [11C] DPA713, and investigated microglial activation in relation to neurological manifestations, especially epilepsy and cognitive function.
This cross-sectional study included 18 patients with TSC (6 in the no-seizure group, 6 in the refractory seizure group, and 6 in the mTOR-inhibitor [mTOR-i] group). All participants underwent [11C] DPA713-PET. PET results were superimposed with a 3D T2-weighted fluid-attenuated inversion-recovery (FLAIR) and T1-weighted image (T1WI) to evaluate the location of cortical tubers. Microglial activation was assessed using the standardized uptake value ratio (SUVr) of DPA713 binding. The volume ratio of the DPA713-positive area to the intracranial volume (volume ratio of DPA713/ICV) was calculated to evaluate the extent of microglial activation. A correlation analysis was performed to examine the relationship between volume ratio of DPA713/ICV and severity of epilepsy and cognitive function.
Most cortical tubers with hyperintensity on FLAIR and hypo- or isointensity on T1WI showed microglial activation. The extent of microglial activation was significantly greater in the refractory seizure group than in the no-seizure or mTOR-i groups (p < 0.001). The extent of microglial activation in subjects without mTOR-i treatment correlated positively with epilepsy severity (r = 0.822, P = 0.001) and negatively with cognitive function (r = -0.846, p = 0.001), but these correlations were not present in the mTOR-i group (r = 0.232, P = 0.658, r = 0.371, P = 0.469, respectively).
Neuroinflammation is associated with the severity of epilepsy and cognitive dysfunction in brains with TSC. mTOR-i may suppress the extent of neuroinflammation in TSC. Investigating the spread of microglial activation using TSPO-PET in these patients may help to predict the progression of neuropathy by assessing the degree of neuroinflammation and therefore be useful for determining how aggressive the treatment should be and in assessing the effectiveness of such treatment in patients with TSC.